FBR Capital Remains Buyers of CVS Health (CVS) Following 'Solid' Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
CVS, Express Scripts 2017 Formulary Exclusion Lists Make Waves
August 2, 2016 11:56 AM EDTOn Monday, CVS Health (NYSE: CVS) released its 2017 Standard Formulary Exclusion List and Express Scripts (NASDAQ: ESRX) released its 2017 National Preferred Formulary exclusion list.
Below is a summary of analyst commentary around the list changes:
CVS 2017 Standard Formulary Exclusion List:
Barclays analyst Eric Percher said most notably, CVS signaled aggressively on biosimilars, replacing Neupogen with Zarxio (limited impact under the pharmacy benefit) and Lantus with Basaglar for 2017 (significant impact under the pharmacy benefit)
Percher noted a therapeutics focus on Oncology,... More
CVS Health (CVS) to Exclude Sanofi's (SNY) Lantus in 2017 from Main Covered Drug List - Bloomberg
August 2, 2016 9:29 AM EDTCVS Health (NYSE: CVS) to Exclude Sanofi's (NYSE: SNY) Lantus in 2017 from Main Covered Drug List - Bloomberg
... MoreCVS Health (CVS) to Exclude Medivation's (MDVN) Xtandi in 2017 Main Formulary - Bloomberg
August 2, 2016 9:10 AM EDTCVS Health (NYSE: CVS) to Exclude Medivation's (Nasdaq: MDVN) Xtandi in 2017 Main Formulary - Bloomberg
... MoreCVS Health (CVS) Tops Q2 EPS by 2c; Boosts FY16 EPS Outlook
August 2, 2016 6:56 AM EDTCVS Health (NYSE: CVS) reported Q2 EPS of $1.32, $0.02 better than the analyst estimate of $1.30. Revenue for the quarter came in at $43.7 billion versus the consensus estimate of $44.28 billion.
Same store sales increased 2.1% versus the second quarter of 2015. Pharmacy same store sales rose 3.9% and... More
